Soundzilla
EN

Скачать «Petauri Evidence» в MP3

Найдено 19 совпадений по запросу «Petauri Evidence». Нажмите «Скачать», чтобы выбрать формат и качество.

  1. Petauri Evidence at ISPOR Annual 2025 - Montreal 0:46

    Petauri Evidence at ISPOR Annual 2025 - Montreal

    Petauri Evidence 0:46 MP3 ~1.1 МБ

  2. Navigating US payer evidence needs to optimise market access 57:35

    Navigating US payer evidence needs to optimise market access

    Petauri Evidence 57:35 MP3 ~79.1 МБ

  3. We are Petauri Evidence 1:05

    We are Petauri Evidence

    Petauri Evidence 1:05 MP3 ~1.5 МБ

  4. What evidence do US payers want to see? 2:01

    What evidence do US payers want to see?

    Petauri Evidence 2:01 MP3 ~2.8 МБ

  5. Designing a Global Market Access Strategy Built for MFN 1:00:12

    Designing a Global Market Access Strategy Built for MFN

    Petauri Evidence 1:00:12 MP3 ~82.7 МБ

  6. What’s Cost Got to Do With It?  - Reviewing  Key Issues Related to Costs in HTA 9:23

    What’s Cost Got to Do With It? - Reviewing Key Issues Related to Costs in HTA

    Petauri Evidence 9:23 MP3 ~12.9 МБ

  7. The dynamic nature of network meta-analysis: how data updates could influence HTA 5:30

    The dynamic nature of network meta-analysis: how data updates could influence HTA

    Petauri Evidence 5:30 MP3 ~7.6 МБ

  8. Communicating value to US Payers: Insights for Pharma and Medtech 59:03

    Communicating value to US Payers: Insights for Pharma and Medtech

    Petauri Evidence 59:03 MP3 ~81.1 МБ

  9. AI in systematic review: accuracy, efficiency and performance 6:38

    AI in systematic review: accuracy, efficiency and performance

    Petauri Evidence 6:38 MP3 ~9.1 МБ

  10. First to Market: Unlocking Switzerland’s Pharma Potential 44:32

    First to Market: Unlocking Switzerland’s Pharma Potential

    Petauri Evidence 44:32 MP3 ~61.2 МБ

  11. World EPA 2025 0:22

    World EPA 2025

    Petauri Evidence 0:22 MP3 ~0.5 МБ

  12. Which types of evidence are valued in the US market? 2:01

    Which types of evidence are valued in the US market?

    Petauri Evidence 2:01 MP3 ~2.8 МБ

  13. Navigating market access: Launch strategies and health economic modelling for medical devices 44:42

    Navigating market access: Launch strategies and health economic modelling for medical devices

    Petauri Evidence 44:42 MP3 ~61.4 МБ

  14. AMCP Dossier Format v5.0: US Payer Preferences and Utilization to Support Formulary Decision Making 6:06

    AMCP Dossier Format v5.0: US Payer Preferences and Utilization to Support Formulary Decision Making

    Petauri Evidence 6:06 MP3 ~8.4 МБ

  15. Highlights from ISPOR Europe 2024 1:04

    Highlights from ISPOR Europe 2024

    Petauri Evidence 1:04 MP3 ~1.5 МБ

  16. What Proportion of the Total Value Generated by New Drugs Accrues to Manufacturers? 5:33

    What Proportion of the Total Value Generated by New Drugs Accrues to Manufacturers?

    Petauri Evidence 5:33 MP3 ~7.6 МБ

  17. Q&A Webinar: The Evolving NHS – An ICS Chief Pharmacist’s Perspective 31:26

    Q&A Webinar: The Evolving NHS – An ICS Chief Pharmacist’s Perspective

    Petauri Evidence 31:26 MP3 ~43.2 МБ

  18. NICE move from MTEP to  HealthTech program: Evolving evidence expectations for medtech HTA 4:43

    NICE move from MTEP to HealthTech program: Evolving evidence expectations for medtech HTA

    Petauri Evidence 4:43 MP3 ~6.5 МБ

  19. Pharma pricing: strategies for loss of exclusivity 3:02

    Pharma pricing: strategies for loss of exclusivity

    Petauri Evidence 3:02 MP3 ~4.2 МБ